Features of management of patients with combined gastroesophageal reflux disease and irritable bowel syndrome
https://doi.org/10.21518/ms2024-546
Abstract
The course of Gastroesophageal reflux disease (GERD), which is a widespread disease, is aggravated by a combination with other diseases, including functional pathology of the gastrointestinal tract, for example, functional dyspepsia or irritable bowel syndrome (IBS). This combination affects not only the clinical features of the disease, but also the effectiveness of GERD therapy, when there are cases of incomplete response to proton pump inhibitors (PPIs). And the doctor is faced with the choice of drugs for the complex treatment of GERD. For example, in the case of a combination of GERD and IBS in complex therapy, it is necessary to consider the use of antispasmodics or normokinetics. On the other hand, when prescribing this or that PPI, it is important to remember that these drugs themselves can affect the treatment response in patients with a combination of GERD and IBS, especially with diarrheal or mixed variants, since some patients may have a reaction to additional PPI components that are necessary for improvement bioavailability of the drug. Thus, the presence of sorbitol, mannitol, and lactose can aggravate the course of IBS, increasing the manifestations of diarrhea. The absence of these additives in the pantoprazole drug allows it to be prescribed for the correction of GERD in combination with IBS, regardless of the variant of the latter. This article will present a clinical example of a patient with a combined course of GERD and IBS, the mutually aggravating influence of both diseases not only from the point of view of patho genetic mechanisms, but also the influence of PPI pharmacotherapy, which is especially important in IBS with diarrhea. Approaches to therapy are considered, primarily the prescription of antisecretory therapy using pantoprazole as an example.
About the Authors
I. G. Pakhomova
Almazov National Medical Research Center
Russian Federation
Russian Federation
Inna G. Pakhomova - Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy with Clinic.
2, Akkuratov St., St Petersburg, 197341
A. A. Lelyakova
Clinic “Bud Zdorov”
Russian Federation
Russian Federation
Alexandra A. Lelyakova – Therapist.
274a, Ligovsky Ave., St Petersburg, 196006
References
1. Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97.
2. Li N, Yang WL, Cai MH, Chen X, Zhao R, Li MT et al. Burden of gastroesophageal reflux disease in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of disease study 2019. BMC Public Health. 2023;23(1):582. https://doi.org/10.1186/s12889-023-15272-z.
3. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. https://doi.org/10.1136/gutjnl-2016-313589.
4. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. https://doi.org/10.1136/gutjnl-2012-304269.
5. Lazebnik LB, Masharova AA, Bordin DS, Vasiliev YuV, Tkachenko EI, Abdulkhakov RA et al. Results of a multicenter trial “Epidemiology of gastroesophageal reflux disease in Russia” (MEGRE). Terapevticheskii Arkhiv. 2011;83(1):45–50. (In Russ.) Available at: https://elibrary.ru/ntmfzf.
6. Dixon MF, Neville PM, Mapstone NP, Moayyedi P, Axon AT. Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastroesophageal reflux? Gut. 2001;49(3):359–363. https://doi.org/10.1136/gut.49.3.359.
7. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407.e5. https://doi.org/10.1053/j.gastro.2016.02.031.
8. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721.e4. https://doi.org/10.1016/j.cgh.2012.02.029.
9. Ford AC, Forman D, Bailey AG. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229–1239. Available at: https://journals.lww.com/ajg/Abstract/2008/05000/Irritable_Bowel_SyndromeA_10_Yr_Natural_History.25.aspx.
10. Simanenkov VI, Maev IV, Tkacheva ON, Alekseenko SA, Andreev DN, Bordin DS et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention (Russian Federation). 2021;20(1):2758. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2758.
11. Ivashkin VT, Maev IV, Shelygin YuA, Baranskaya EK, Belous SS, Belousova EA et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-74-95.
12. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401–409. https://doi.org/10.1016/j.cgh.2009.07.020.
13. Rasmussen S, Jensen TH, Henriksen SL, Haastrup PF, Larsen PV, Søndergaard J, Jarbøl DE. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162–169. https://doi.org/10.3109/00365521.2014.983157.
14. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. https://doi.org/10.1159/000211715.
15. de Bortoli N, Martinucci I, Bellini M, Savarino E, Savarino V, Blandizzi C, Marchi S. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787–5797. https://doi.org/10.3748/wjg.v19.i35.5787.
16. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107(12):1793–1801. https://doi.org/10.1038/ajg.2012.336.
17. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.e2. https://doi.org/10.1053/j.gastro.2016.02.032.
18. Stanghellini V, Barbara G, Cogliandro R, Salvioli B, Cremon C, De Giorgio R, Corinaldesi R. Overlap between GERD and IBS: irrefutable but subtle. J Clin Gastroenterol. 2007;41:S114–S117. https://doi.org/10.1097/MCG.0b013e31803d0f94.
19. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304(6819):87–90. https://doi.org/10.1136/bmj.304.6819.87.
20. de Bortoli N, Natali V, Melissari S, Simonetti N, Tapete G, Marchi S. Overlap of GERD and gastrointestinal functional disorders. Minerva Gastroentrol Dietol. 2017;63(3):205–220. https://doi.org/10.23736/S1121-421X.17.02398-4.
21. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328. https://doi.org/10.1038/ajg.2012.444.
22. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2006;23(10):1473–1477. https://doi.org/10.1111/j.1365-2036.2006.02911.x.
23. Garros A, Mion F, Marjoux S, Damon H, Roman S. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis Esophagus. 2016;29(7):787–793. https://doi.org/10.1111/dote.12374.
24. Mönnikes H, Heading RC, Schmitt H, Doerfler H. Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. World J Gastroenterol. 2011;17(27):3235–3241. Available at: https://www.wjgnet.com/1007-9327/full/v17/i27/3235.htm.
25. Kinoshita Y, Miwa H, Sanada K, Miyata K, Haruma K. Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. J Gastroenterol. 2014;49(4):628–637. https://doi.org/10.1007/s00535-013-0812-3.
26. Mönnikes H, Schwan T, van Rensburg C, Straszak A, Theek C, Sander P, Lühmann R. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2012;35(11):1279–1289. https://doi.org/10.1111/j.1365-2036.2012.05085.x.
27. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504–508. https://doi.org/10.1016/j.cgh.2009.12.022.
28. Van den Houte K, Colomier E, Routhiaux K, Mariën Z, Schol J, Van den Bergh J et al. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. Gastroenterology. 2024;167(2):333–342. https://doi.org/10.1053/j.gastro.2024.02.008.
29. de Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018;31(6):639–648. https://doi.org/10.20524/aog.2018.0314.
30. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Lawrence R Schiller et al. American College of Gastroenterilogy monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2–S26. https://doi.org/10.1038/ajg.2014.187.
31. Butorova LI, Tokmulina GM, Plavnik TE, Rassypnova LI, Mamieva ZA. Roman criteria IV irritable intestine syndrome: evolution of views on pathogenesis, diagnostics and treatment. Lechaschi Vrach. 2017;(3):61–64. (In Russ.) Available at: https://www.lvrach.ru/2017/03/15436690.
32. Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49(43):193–197. Available at: https://pubmed.ncbi.nlm.nih.gov/11941952/.
33. Ivashkin VT, Trukhmanov AS, Gonik MI. Rebamipide using in gastroesophageal reflux disease treatment. Terapevticheskii Arkhiv. 2020;92(4):98–104. (In Russ.) https://doi.org/10.26442/00403660.2020.04.000568.
34. Исаков ВА. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: Академкнига; 2001. 304 с. Режим доступа: https://elibrary.ru/wkasaj.
35. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs. 1996;51(3):460–482. https://doi.org/10.2165/00003495-199651030-00012.
36. Koop H, Kuly S, Flüg M, Eissele R, Mönnikes H, Rose K et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol. 1996;8(9):915–918. Available at: https://pubmed.ncbi.nlm.nih.gov/8889461/.
37. Corinaldesi R, Valentini M, Belaïche J, Colin R, Geldof H, Maier C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther. 1995;9(6):667–671. https://doi.org/10.1111/j.1365-2036.1995.tb00437.x.
38. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37–47. https://doi.org/10.1111/j.1365-2036.2012.05106.x.
Review
For citations:
Pakhomova IG, Lelyakova AA. Features of management of patients with combined gastroesophageal reflux disease and irritable bowel syndrome. Meditsinskiy sovet = Medical Council. 2024;(23):104-111. (In Russ.) https://doi.org/10.21518/ms2024-546
Views:
361
Email this article 